Join Apnimed for a virtual investor event featuring key opinion leaders (KOLs) Douglas Kirsch, MD, FAAN, FAASM (Wake Forest University), and Nathaniel Watson, MD, MSc, FAAN, FAASM (University of Washington), who will join company management to discuss the unmet medical need and evolving treatment landscape for patients with obstructive sleep apnea (OSA).

The event will share new data to provide context and insight for how pharmacotherapies will change the OSA treatment paradigm, highlighting AD109, Apnimed’s investigational drug that directly addresses the underlying neuromuscular cause of upper airway collapse in patients with OSA. Company management will also provide an update about the ongoing Phase 3 trials, and Apnimed’s go-to-market strategy to unlock the blockbuster potential of AD109.

A live question and answer session will follow the presentations and KOL discussion.